RecruitingNot ApplicableNCT05721677

CLABSI Prevention With Tissue Adhesive

The Impact of Central-line Exit-site Sealing With 2-octyl Cyanoacrylate Adhesive on CLABSI in Pediatric Cardiac Intensive Care Unit

Sponsor

Rabin Medical Center

Enrollment

600 participants

Start Date

Mar 15, 2023

Study Type

INTERVENTIONAL

Conditions

Central Line Associated Blood Stream Infections (CLABSI)

Summary

Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.

Eligibility

Min Age: 0 DaysMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called 2-octyl cyanoacrylate based topical skin adhesive for people with central line associated blood stream infections (clabsi). The study is currently recruiting participants at 1 location. People eligible for this study include aged 0 Days to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.